Pompe Drug Shortage Forces Clinics to Rethink Operations and Revenue

Sanofi’s reported shortage of Myozyme and Nexviazyme for Pompe disease is a practical shock for clinics that deliver rare-disease infusions. For busy providers, the risk isn’t only patient harm — it’s schedule disruption, reimbursement pressure, and operational overhead that can ripple through a practice.

Immediate operational impact: triage, documentation, and clinic flow

Clinics must triage scarce supply, convert treatment plans, and manage patient communications while avoiding unsafe substitutions. That creates urgent workflow demands: extra prior-authorizations, intensive case management, and ad-hoc scheduling to consolidate infusion slots — all of which increase staff time per patient and reduce throughput.

Revenue effects are tangible. Missed or shortened infusion appointments lower billable services and can trigger contractual penalties under buy-and-bill arrangements. For practices participating in value-based care, quality measures and outcomes can suffer if therapy gaps widen — which in turn threatens shared savings and performance bonuses.

Practical steps: use tech, tighten workflows, protect revenue

Short-term fixes and medium-term investments reduce impact. Use your EHR systems to flag affected patients, create standardized documentation templates for shortage-driven dosing changes or deferred infusions, and automate outreach messaging. Integrate specialty pharmacy coordination into the EHR to track allocations and authorization status in one place — this cuts duplicative calls and prevents lost charges.

Leverage digital health and AI tools where available: simple remote-monitoring programs can maintain clinical oversight when infusions are delayed, and AI in healthcare can help forecast patient-level risk so you prioritize those most likely to deteriorate. From a revenue perspective, proactively documenting clinical necessity preserves payer appeals and supports coding for supply-related clinical exceptions.

• Triage with data: use EHR registries to rank patients by clinical risk and recent progression to guide limited-dose allocation.
• Document proactively: add shortage-specific templates and attach specialty pharmacy correspondence to encounters to protect reimbursement and appeals.
• Use digital monitoring and AI: deploy telehealth check-ins and predictive alerts to spot deterioration early and justify prioritized care under value-based contracts.

Sanofi’s shortage is a reminder that medication supply shocks are a systems problem — one where clinics that blend tight operational controls with digital health and AI-informed triage will fare better. For providers in rare-disease programs, the immediate goal is continuity of safe care; the near-term business goal is preserving revenue and value-based metrics while demand and supply stabilize.